<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01632709</url>
  </required_header>
  <id_info>
    <org_study_id>DOD_PAP 12</org_study_id>
    <nct_id>NCT01632709</nct_id>
  </id_info>
  <brief_title>Pathophysiology of Post Amputation Pain</brief_title>
  <acronym>PPAP</acronym>
  <official_title>Pathophysiology of Post Amputation Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shirley Ryan AbilityLab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shirley Ryan AbilityLab</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see how Post Amputation Pain (PAP) affects the body and brain
      by using sensory testing (such as pinprick testing), taking pictures of your brain (using a
      functional magnetic resonance imaging (fMRI) machine) and biomedical interventions (such as
      an injection of pain medicine). All medicines and the fMRI machine used during this study are
      FDA approved. The investigators hope that by learning the causes of PAP, the investigators
      can help future amputees.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Your participation in this study will last for 5 weeks and you will be asked to come to a
      total of 3 visits. The first visit will be during the first week of the study, the second
      visit during the second week of the study and the third (final) visit will be during the
      fifth (and final) week of the study. For your first visit you will have a physical
      examination with some sensory stimulation tests (such as vibration and pinprick tests), some
      questionnaires about your health and pain history, hot and cold sensory tests, and we will
      take thermal pictures of your body before and after receiving a quick electrical stimulus.
      You will also be trained on how to use the finger-span device to rate your pain during the
      second visit, and how to use an electronic pain diary to record your pain scores three times
      a day during the five weeks of the study.

      The second visit will begin with questionnaires from the first visit and thermal images with
      a quick electrical stimulus. You will then be brought to an fMRI scanner room at Northwestern
      University. For an hour and fifteen minutes we will take pictures of your brain and these
      pictures will help us understand the changes in your brain relating to pain. You will then be
      put into one of four treatment groups randomly.

      The study treatment that you will get will be decided randomly or by chance, like flipping a
      coin. Injections in this study will use the local anesthetic bupivacaine (a long lasting drug
      like the numbing agent novocaine used by dentists). This drug causes numbness, blocks pain
      and other nerve function near the injection site for 6-8 hours. Group 1 will get a
      sympathetic nerve block of bupivacaine, which changes how your nerves transmit pain, in
      either the neck or lower back (depending on where the amputation is located), Group 2 will
      get a placebo injection (no active medicine) in either the neck or lower back (depending on
      where the amputation is located), Group 3 will get a neuroma injection of bupivacaine (a
      neuroma is a group of nerves at the end of your residual limb), and Group 4 will get a
      placebo injection (no active medicine) at the neuroma. Some people get the bupivacaine
      injection and some people get the placebo injection so that we can compare the groups and see
      if the bupivacaine brings more, less or the same pain relief as a placebo injection. We scan
      your brain before the injection so that we can see how your brain responds to pain. We also
      scan your brain after the injection so that we can see if your brain responds differently to
      pain after the injection has been done.

      You will know the location of your injection before you receive the treatment (neck, lower
      back or neuroma on your affected limb), but you will not know if you are getting a pain
      medication injection or placebo injection. Only the study doctors will know this information,
      and it can be told to you in case of an emergency. After the injection, you will have a
      second hour of brain scanning. After the scanning, you will be asked to complete some
      questionnaires, sensory tests, hot and cold temperature testing and we will take thermal
      pictures of your body before and after a quick electrical stimulus.

      Your third visit will be four weeks after your second visit. For your third visit you will
      have the same questionnaires as during the first and second visits, sensory tests, hot and
      cold temperature testing and we will take thermal pictures of your body before and after a
      quick electrical stimulus.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain</measure>
    <time_frame>Pain rating before and at 15 minutes and 1 hour post injection</time_frame>
    <description>Pain rating before and after injection on a 0-10 NRS pain scale (0=no pain, 10= worst pain imaginable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Perceived Disability (PDI)</measure>
    <time_frame>PDI collected pre injection and 1 week post injection</time_frame>
    <description>The PDI is a seven-item validated instrument that assesses perceived disability in 7 key life areas. The Pain Disability Scale is a scale from 0-70 where 0= no disability and 70=the most disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Perceived Anxiety (PASS)</measure>
    <time_frame>PASS collected pre injection and 1 week post injection</time_frame>
    <description>The Pain Anxitey Symptoms Scale (PASS) is a validated instrument that assesses anxiety in.The PASS is a scale from 0-100 where 0= no anxiety and 100=the most anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Depression (CES-D 10)</measure>
    <time_frame>CES-D 10 collected pre injection and 1 week post injection</time_frame>
    <description>The Center for Epidemiologic Studies Short Depression Scale (CES‚ÄêD 10) is a validated instrument that assesses depression. The CES-D 10 is a scale from 0-30 where 0= no depression and 30=the most depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Visual Analogue Scale (VAS)</measure>
    <time_frame>VAS collected pre injection and 1 week post injection</time_frame>
    <description>The Pain Visual Analogue Scale (VAS) is a scale from 0-100 where 0= no pain and 100=the worst pain</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Amputation Stumps</condition>
  <condition>Neuroma</condition>
  <arm_group>
    <arm_group_label>Sympathetic nerve block of bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sympathetic nerve block of bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dry needling at the sympathetic ganglion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo/ Dry needling at the sympathetic ganglion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neuroma injection of bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neuroma injection of bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dry needling at the neuroma</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo/ dry needling at the neuroma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>one injection of 10ml of .25%</description>
    <arm_group_label>Sympathetic nerve block of bupivacaine</arm_group_label>
    <arm_group_label>Neuroma injection of bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dry needling</description>
    <arm_group_label>Dry needling at the sympathetic ganglion</arm_group_label>
    <arm_group_label>dry needling at the neuroma</arm_group_label>
    <other_name>Dry needling</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 18 years old

          2. Able to read and speak English and provide informed consent

          3. Single Amputation, upper or lower.

          4. Subject has chronic post amputation pain lasting longer than three months

          5. Subject has healed amputation wounds

          6. Pain must be ‚â•3 on a scale of 0-10, 0 being no pain, 10 being the worse pain
             imaginable.

          7. If subjects pain is non-existent during fMRI scans, the subject needs to be willing to
             have their pain induced by targeting pain trigger points (for example, study's
             postdoctoral fellow would massage certain regions of the affected limb to trigger
             PAP).

          8. Subject agrees to 1) Stop taking all aspirin seven days prior to their second visit
             (Bayer,Ecotrin,Alka Seltzer, etc.) 2) All inflammatory medications 48 hours prior to
             their second visit (Advil, Motrin, Indocin, Lodine , Ibuprofen, Aleve, Naproxen, etc.
             3) Supplements such as Vitamin E and Fish Oil 48 hours prior to their second visit.

          9. Subject agrees to continue other prescribed medications.

         10. Subject is willing to have hypodermic needle injections and images taken of them
             (digital, thermal, and fMRI).

         11. Able to understand and comply with all data collection methodology including
             electronic diary.

         12. If female, is not pregnant and not currently attempting to conceive; if of
             childbearing potential, use of a highly effective method of birth control (as
             determined by Pl).

        Exclusion Criteria:

          1. Subject is allergic to Isovue 300 or amide-type local anesthetics such as bupivicaine,
             lidocaine, or mepivacaine.

          2. Subject has a diagnosis of bleeding diathesis or an immune compromise.

          3. Subject has pain that is more severe than their post amputation pain.

          4. Subject has a clinical diagnosis of fibromyalgia.

          5. Subject has metal shavings and or is frequently in an environment where there is metal
             work being done or significant amounts of metal shavings.

          6. Subject has ferrous metal implants, aneurism clips, bioelectric devices, and other
             implants which can be affected by the magnetic field of the MRI.

          7. Subject is claustrophobic.

          8. Subject weighs more than 300 pounds.

          9. Subject plans to start new pain treatments or therapies during the study (e.g. new
             pain medication, injections, PT, surgery).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Harden, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shirley Ryan AbilityLab</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rehabilitation Institute of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2012</study_first_submitted>
  <study_first_submitted_qc>July 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2012</study_first_posted>
  <results_first_submitted>June 1, 2015</results_first_submitted>
  <results_first_submitted_qc>July 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2015</results_first_posted>
  <last_update_submitted>July 20, 2015</last_update_submitted>
  <last_update_submitted_qc>July 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shirley Ryan AbilityLab</investigator_affiliation>
    <investigator_full_name>Dr. Norman Harden</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Subjects were not assigned to an arm until Visit 2 (randomization).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sympathetic Nerve Block of Bupivacaine</title>
        </group>
        <group group_id="P2">
          <title>Dry Needling at Sympathetic Ganglion</title>
        </group>
        <group group_id="P3">
          <title>Neuroma Injection of Bupivacaine</title>
        </group>
        <group group_id="P4">
          <title>Dry Needling at the Neuroma</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Visit 2 (Received Injection)</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sympathetic Nerve Block of Bupivacaine</title>
        </group>
        <group group_id="B2">
          <title>Dry Needling at Sympathetic Ganglion</title>
        </group>
        <group group_id="B3">
          <title>Neuroma Injection of Bupivacaine</title>
        </group>
        <group group_id="B4">
          <title>Dry Needling at the Neuroma</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.8" spread="11.9"/>
                    <measurement group_id="B2" value="55" spread="8.5"/>
                    <measurement group_id="B3" value="50.4" spread="9.4"/>
                    <measurement group_id="B4" value="43.3" spread="7"/>
                    <measurement group_id="B5" value="53.4" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain</title>
        <description>Pain rating before and after injection on a 0-10 NRS pain scale (0=no pain, 10= worst pain imaginable)</description>
        <time_frame>Pain rating before and at 15 minutes and 1 hour post injection</time_frame>
        <population>all available data was analyzed (some subjects did not complete all outcomes)</population>
        <group_list>
          <group group_id="O1">
            <title>Sympathetic Nerve Block of Bupivacaine</title>
            <description>Bupivacaine: one injection of 10ml of .25%</description>
          </group>
          <group group_id="O2">
            <title>Dry Needling</title>
            <description>Placebo: Dry needling</description>
          </group>
          <group group_id="O3">
            <title>Neuroma Injection of Bupivacaine</title>
            <description>Bupivacaine: one injection of 10ml of .25%</description>
          </group>
          <group group_id="O4">
            <title>Dry Needling at the Neuroma</title>
            <description>Placebo: Dry needling</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain</title>
          <description>Pain rating before and after injection on a 0-10 NRS pain scale (0=no pain, 10= worst pain imaginable)</description>
          <population>all available data was analyzed (some subjects did not complete all outcomes)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NRS-Phantom Limb Pain (15 minutes post)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.3"/>
                    <measurement group_id="O2" value="-2" spread="0"/>
                    <measurement group_id="O3" value="-1" spread="2.3"/>
                    <measurement group_id="O4" value="1.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NRS-Phantom Limb Pain (1 hour post)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="0.7"/>
                    <measurement group_id="O2" value="-1" spread="1.4"/>
                    <measurement group_id="O3" value="-0.3" spread="0.6"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NRS-Residual Limb Pain (15 minutes post)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.5"/>
                    <measurement group_id="O2" value="-1" spread="1.4"/>
                    <measurement group_id="O3" value="-2.2" spread="3.5"/>
                    <measurement group_id="O4" value="0.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NRS-Residual Limb Pain (1 hour post)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="2.8"/>
                    <measurement group_id="O2" value="-0.5" spread="0.7"/>
                    <measurement group_id="O3" value="0.3" spread="1.5"/>
                    <measurement group_id="O4" value="3" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Perceived Disability (PDI)</title>
        <description>The PDI is a seven-item validated instrument that assesses perceived disability in 7 key life areas. The Pain Disability Scale is a scale from 0-70 where 0= no disability and 70=the most disability</description>
        <time_frame>PDI collected pre injection and 1 week post injection</time_frame>
        <population>all available data was analyzed (some subjects did not complete all outcomes)</population>
        <group_list>
          <group group_id="O1">
            <title>Sympathetic Nerve Block of Bupivacaine</title>
            <description>Bupivacaine: one injection of 10ml of .25%</description>
          </group>
          <group group_id="O2">
            <title>Dry Needling</title>
            <description>Placebo: Dry needling</description>
          </group>
          <group group_id="O3">
            <title>Neuroma Injection of Bupivacaine</title>
            <description>Bupivacaine: one injection of 10ml of .25%</description>
          </group>
          <group group_id="O4">
            <title>Dry Needling at the Neuroma</title>
            <description>Placebo: Dry needling</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Perceived Disability (PDI)</title>
          <description>The PDI is a seven-item validated instrument that assesses perceived disability in 7 key life areas. The Pain Disability Scale is a scale from 0-70 where 0= no disability and 70=the most disability</description>
          <population>all available data was analyzed (some subjects did not complete all outcomes)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.5" spread="10.6"/>
                    <measurement group_id="O2" value="-21.5" spread="24.7"/>
                    <measurement group_id="O3" value="-5.2" spread="12.7"/>
                    <measurement group_id="O4" value="13.0" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Perceived Anxiety (PASS)</title>
        <description>The Pain Anxitey Symptoms Scale (PASS) is a validated instrument that assesses anxiety in.The PASS is a scale from 0-100 where 0= no anxiety and 100=the most anxiety</description>
        <time_frame>PASS collected pre injection and 1 week post injection</time_frame>
        <population>all available data was analyzed (some subjects did not complete all outcomes)</population>
        <group_list>
          <group group_id="O1">
            <title>Sympathetic Nerve Block of Bupivacaine</title>
            <description>Bupivacaine: one injection of 10ml of .25%</description>
          </group>
          <group group_id="O2">
            <title>Dry Needling</title>
            <description>Placebo: Dry needling</description>
          </group>
          <group group_id="O3">
            <title>Neuroma Injection of Bupivacaine</title>
            <description>Bupivacaine: one injection of 10ml of .25%</description>
          </group>
          <group group_id="O4">
            <title>Dry Needling at the Neuroma</title>
            <description>Placebo: Dry needling</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Perceived Anxiety (PASS)</title>
          <description>The Pain Anxitey Symptoms Scale (PASS) is a validated instrument that assesses anxiety in.The PASS is a scale from 0-100 where 0= no anxiety and 100=the most anxiety</description>
          <population>all available data was analyzed (some subjects did not complete all outcomes)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="8.5"/>
                    <measurement group_id="O2" value="-36.5" spread="5.0"/>
                    <measurement group_id="O3" value="-1.0" spread="17.4"/>
                    <measurement group_id="O4" value="11.3" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Depression (CES-D 10)</title>
        <description>The Center for Epidemiologic Studies Short Depression Scale (CES‚ÄêD 10) is a validated instrument that assesses depression. The CES-D 10 is a scale from 0-30 where 0= no depression and 30=the most depression</description>
        <time_frame>CES-D 10 collected pre injection and 1 week post injection</time_frame>
        <population>all available data was analyzed (some subjects did not complete all outcomes)</population>
        <group_list>
          <group group_id="O1">
            <title>Sympathetic Nerve Block of Bupivacaine</title>
            <description>Bupivacaine: one injection of 10ml of .25%</description>
          </group>
          <group group_id="O2">
            <title>Dry Needling</title>
            <description>Placebo: Dry needling</description>
          </group>
          <group group_id="O3">
            <title>Neuroma Injection of Bupivacaine</title>
            <description>Bupivacaine: one injection of 10ml of .25%</description>
          </group>
          <group group_id="O4">
            <title>Dry Needling at the Neuroma</title>
            <description>Placebo: Dry needling</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Depression (CES-D 10)</title>
          <description>The Center for Epidemiologic Studies Short Depression Scale (CES‚ÄêD 10) is a validated instrument that assesses depression. The CES-D 10 is a scale from 0-30 where 0= no depression and 30=the most depression</description>
          <population>all available data was analyzed (some subjects did not complete all outcomes)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="2.8"/>
                    <measurement group_id="O2" value="-4.0" spread="2.8"/>
                    <measurement group_id="O3" value="-2.0" spread="6.5"/>
                    <measurement group_id="O4" value="3.3" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Visual Analogue Scale (VAS)</title>
        <description>The Pain Visual Analogue Scale (VAS) is a scale from 0-100 where 0= no pain and 100=the worst pain</description>
        <time_frame>VAS collected pre injection and 1 week post injection</time_frame>
        <population>all available data was analyzed (some subjects did not complete all outcomes)</population>
        <group_list>
          <group group_id="O1">
            <title>Sympathetic Nerve Block of Bupivacaine</title>
            <description>Bupivacaine: one injection of 10ml of .25%</description>
          </group>
          <group group_id="O2">
            <title>Dry Needling</title>
            <description>Placebo: Dry needling</description>
          </group>
          <group group_id="O3">
            <title>Neuroma Injection of Bupivacaine</title>
            <description>Bupivacaine: one injection of 10ml of .25%</description>
          </group>
          <group group_id="O4">
            <title>Dry Needling at the Neuroma</title>
            <description>Placebo: Dry needling</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Visual Analogue Scale (VAS)</title>
          <description>The Pain Visual Analogue Scale (VAS) is a scale from 0-100 where 0= no pain and 100=the worst pain</description>
          <population>all available data was analyzed (some subjects did not complete all outcomes)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in VAS- Phantom Limb Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="36.1"/>
                    <measurement group_id="O2" value="-8.0" spread="8.5"/>
                    <measurement group_id="O3" value="-4.4" spread="42.6"/>
                    <measurement group_id="O4" value="10.8" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in VAS-Residual Limb Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="18.4"/>
                    <measurement group_id="O2" value="-10.8" spread="7.4"/>
                    <measurement group_id="O3" value="-9.5" spread="20.6"/>
                    <measurement group_id="O4" value="5" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo/Sham Injection</title>
        </group>
        <group group_id="E2">
          <title>Treatment Group</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Center for Pain Studies</name_or_title>
      <organization>Rehabilitation Institute of Chicago</organization>
      <phone>312.238.5654</phone>
      <email>centerforpainstudies@ric.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

